Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Chief Financial Officer | May 04, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date May 04, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2028-06-07 | Direct | 95,060 |
Reported balance
After 2026-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 95,060 · Balance 95,060 F1: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2030-01-12 | Direct | 47,530 |
Reported balance
After 2026-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-04 · Grant · Acquired 47,530 · Balance 47,530 F1: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-12-17 | Direct | 11,882 |
Reported balance
After 2026-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-04 · Grant · Acquired 11,882 · Balance 11,882 F1: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2031-06-09 | Direct | 33,271 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Grant · Acquired 33,271 · Balance 33,271 F1: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2032-01-23 | Direct | 95,060 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Grant · Acquired 95,060 · Balance 95,060 F1: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.98 · Expires 2034-11-12 | Direct | 92,683 |
Reported balance
After 2026-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-04 · Grant · Acquired 92,683 · Balance 92,683 F2: This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2028-06-07 | IndirectBy Spouse | 33,271 |
Reported balance
After 2026-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-04 · Grant · Acquired 33,271 · Balance 33,271 F1: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested.
F2: This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 33,271 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 7 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 33,271 Underlying: Common Stock · 33,271 shares Expires 2028-06-07 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 92,683 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 6 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,683 Underlying: Common Stock · 92,683 shares Expires 2034-11-12 F2 · derivative.exercise_date: This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 95,060 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 5 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,060 Underlying: Common Stock · 95,060 shares Expires 2032-01-23 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 33,271 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 4 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,271 Underlying: Common Stock · 33,271 shares Expires 2031-06-09 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 11,882 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 3 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,882 Underlying: Common Stock · 11,882 shares Expires 2030-12-17 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 47,530 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 2 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,530 Underlying: Common Stock · 47,530 shares Expires 2030-01-12 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:38 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 95,060 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001140361-26-019376 · form4.xml · derivative · entry 1 Eastling Thomas Wilson · CIK 0001958487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,060 Underlying: Common Stock · 95,060 shares Expires 2028-06-07 F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:22 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001140361-25-021793 · form4.xml · derivative · entry 1 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 21:27 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-25-014601 · form4.xml · derivative · entry 2 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,652 Underlying: Common Stock · 15,000 shares Expires 2033-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 21:27 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 15,000 | $6.93 | $103,950.00 |
DisclosureSEC source: 0001140361-25-014601 · form4.xml · nonDerivative · entry 1 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 00:58 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037708 · form4.xml · derivative · entry 1 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050619 · form4.xml · derivative · entry 2 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2033-10-31 F2 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 314,652 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050619 · form4.xml · derivative · entry 1 Eastling Thomas Wilson · CIK 0001958487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,652 Underlying: Common Stock · 314,652 shares Expires 2033-10-31 F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.